Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, January 10, 2023
Information
Tags: 
Research, Medical Devices, Neurology, Health Technology, Biotechnology, Radiology, Health, Pharmaceutical, Science, PET, Brain, Positron emission tomography, Rapunzel's Tangled Adventure (season 2), Non-fungible token, Acceleration, Therapy, Research, Human, Neurodegeneration, Medical imaging, Pharmaceutical industry
Geotags: 
UNITED STATES, NORTH AMERICA, CANADA, MASSACHUSETTS
⚠ partially generated by AI ↴
Organisation: 
CERVEAU TECHNOLOGIES, CERVEAU TECHNOLOGIES, INC.
Summary
Key Points: 
  • NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
  • The collaboration is focused on using [F-18]MK-6240 as a biomarker in Prothena’s neurodegenerative disease drug research and development.
  • The companies will apply [F-18]MK-6240 imaging to evaluate Prothena’s investigational therapeutics for potential treatment of neurodegenerative diseases in humans, with a focus on Alzheimer’s Disease.
  • Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”


Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

The collaboration is focused on using [F-18]MK-6240 as a biomarker in Prothena’s neurodegenerative disease drug research and development. The companies will apply [F-18]MK-6240 imaging to evaluate Prothena’s investigational therapeutics for potential treatment of neurodegenerative diseases in humans, with a focus on Alzheimer’s Disease.

“Cerveau is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative diseases,” said Rick Hiatt, Chief Executive Officer, Cerveau Technologies, Inc. “We are excited to add Prothena to our growing network of pharmaceutical partners and global validated production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”

About Cerveau Technologies, Inc.

Cerveau’s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.

Copyright: 
Copyright Business Wire 2023